Law Firm Reminds ARS Pharmaceuticals Investors of Class Action Lawsuit Deadline
Faruqi & Faruqi, LLP is reminding investors of the October 5, 2026 deadline to seek lead plaintiff status in a federal class action lawsuit against ARS Pharmaceuticals Inc. The suit alleges the company and its executives made misleading statements.
New York, NY – September 24, 2026 – Law firm Faruqi & Faruqi, LLP is investigating potential claims against ARS Pharmaceuticals Inc. (NASDAQ: SPRY) and reminding investors that October 5, 2026, is the deadline to seek lead plaintiff status in a federal securities class action filed against the company.
The complaint alleges that the company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose material adverse facts concerning the expected timeline for expanded insurance coverage for neffy through CVS Caremark. This allegedly caused the plaintiff and other shareholders to purchase ARS securities at artificially inflated prices.
On June 24, 2026, after market close, ARS announced that no new commercial formulary additions or coverage decisions had been issued for neffy in the July 1, 2026 cycle, and that CVS Caremark postponed its decision on expanded coverage until January 2027. Following this news, ARS's stock price fell $2.52, or 23.9%, to close at $8.02 per share on June 25, 2026.
Faruqi & Faruqi, LLP, a national securities law firm, urges investors who suffered losses in ARS Pharmaceuticals to contact partner Josh Wilson directly to discuss their legal rights and options. Investors who suffered losses must contact Faruqi & Faruqi by October 5, 2026, to potentially lead the litigation.